A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer

Chih Ming Su, Ting Yu Chang, Hui Ping Hsu, Hui Huang Lai, Jie Ning Li, Yu Jhen Lyu, Kuang Tai Kuo, Ming Te Huang, Jen Liang Su, Pai Sheng Chen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) is commonly overexpressed in breast cancer and is associated with poor clinical outcomes; however, an increasing number of patients have shown a poor effective response to EGFR tyrosine kinase inhibitors (EGFR-TKI). Here, we found that AXL expression was positively correlated with poor progression in breast cancer patients. Suppression of AXL by an anti-tumor protein, E1A, enhanced EGFR-TKI (gefitinib, erlotinib and lapatinib) sensitization, resulting in significant inhibition of tumor growth in breast cancer cells. Additionally, AXL overexpression dramatically impaired E1A-mediated EGFR-TKI sensitization. These findings show that downregulation of AXL expression by E1A contributes to sensitization to EGFE-TKI in breast cancer, suggesting that combinatorial therapy of AXL inhibitors or E1A gene therapy with EGFR-TKI may be a potential therapeutic strategy for treatment of breast cancer patients.

Original languageEnglish
Pages (from-to)63924-63936
Number of pages13
JournalOncotarget
Volume7
Issue number39
DOIs
Publication statusPublished - 2016

    Fingerprint

Keywords

  • Combination therapy
  • E1A

ASJC Scopus subject areas

  • Oncology

Cite this

Su, C. M., Chang, T. Y., Hsu, H. P., Lai, H. H., Li, J. N., Lyu, Y. J., Kuo, K. T., Huang, M. T., Su, J. L., & Chen, P. S. (2016). A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer. Oncotarget, 7(39), 63924-63936. https://doi.org/10.18632/oncotarget.11737